15.13

0.00% +0.00

Merrimack Pharmaceuticals Inc (MACK)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Merrimack Pharmaceuticals Inc stock is currently priced at $15.13, with a 24-hour trading volume of 1.26M. It has seen a +0.00% increased in the last 24 hours and a +3.07% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $15.13 pivot point. If it approaches the $15.12 support level, significant changes may occur.

Previous Close:

$15.13

Open:

$15.15

24h Volume:

1.26M

Market Cap:

$223.75M

Revenue:

Net Income/Loss:

$-1.18M

P/E Ratio:

-137.55

EPS:

-0.11

Net Cash Flow:

$-1.52M

1W Performance:

+0.07%

1M Performance:

+3.07%

6M Performance:

+18.02%

1Y Performance:

+18.02%

1D Range:

$15.13

$15.16

52W Range:

$11.53

$15.89

Merrimack Pharmaceuticals Inc Stock (MACK) Company Profile

Name

Merrimack Pharmaceuticals Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

617-441-1000

Address

One Kendall Square, Suite B7201, Cambridge

Employee

Twitter

@merrimackpharma

Next Earnings Date

2024-06-05

Latest SEC Filings

MACK's Discussions on Twitter

Merrimack Pharmaceuticals Inc Stock (MACK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-07-16	Downgrade	JP Morgan	Overweight → Neutral
May-27-16	Initiated	Robert W. Baird	Neutral
Dec-23-15	Reiterated	Mizuho	Buy
Oct-27-15	Reiterated	Oppenheimer	Outperform
Apr-21-15	Reiterated	Mizuho	Buy
Oct-10-14	Resumed	Oppenheimer	Outperform
Jul-08-14	Resumed	Brean Capital	Buy
Jun-20-14	Reiterated	Oppenheimer	Outperform
Aug-09-13	Reiterated	Oppenheimer	Outperform
Jun-25-13	Initiated	Mizuho	Buy
May-08-12	Initiated	Oppenheimer	Outperform

View All

Merrimack Pharmaceuticals Inc Stock (MACK) Latest News

Merrimack Pharmaceuticals Inc [MACK] stock for 11441 USD was acquired by Andersen Eric – Knox Daily - Knox Daily

Knox Daily

Contrasting Merrimack Pharmaceuticals (NASDAQ:MACK) & Foghorn Therapeutics (NASDAQ:FHTX) - Defense World

Defense World

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Declares Dividend Increase - $15.10 Per Share - MarketBeat

MarketBeat

StockNews.com Downgrades Merrimack Pharmaceuticals (NASDAQ:MACK) to Sell - Defense World

Defense World

Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts - Yahoo Canada Shine On

Yahoo Canada Shine On

(MACK) On The My Stocks Page - Stock Traders Daily

Stock Traders Daily

Merrimack Pharmaceuticals Inc Stock (MACK) Financials Data

Merrimack Pharmaceuticals Inc (MACK) Net Income 2024

MACK net income (TTM) was -$1.18 million for the quarter ending December 31, 2023, a +23.51% increase year-over-year.

Merrimack Pharmaceuticals Inc (MACK) Cash Flow 2024

MACK recorded a free cash flow (TTM) of -$1.52 million for the quarter ending December 31, 2023, a +12.63% increase year-over-year.

Merrimack Pharmaceuticals Inc (MACK) Earnings per Share 2024

MACK earnings per share (TTM) was -$0.08 for the quarter ending December 31, 2023, a +27.27% growth year-over-year.

Merrimack Pharmaceuticals Inc Stock (MACK) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Andersen Eric	Director	Dec 26 '23	Buy	13.15	48,693	640,313	533,151
Andersen Eric	Director	Dec 07 '23	Buy	12.85	101,050	1,298,472	1,735,600
Andersen Eric	Director	Nov 17 '23	Buy	12.50	300	3,750	1,659,216
Andersen Eric	Director	Nov 14 '23	Buy	12.50	50,170	627,125	1,658,981
Andersen Eric	Director	Nov 09 '23	Buy	12.19	9,975	121,618	1,577,704
Andersen Eric	Director	Nov 08 '23	Buy	12.13	13,823	167,701	1,569,894
CROCKER GARY L	See Remarks	Aug 11 '23	Buy	12.43	2,000	24,865	133,105
CROCKER GARY L	See Remarks	Aug 10 '23	Buy	12.52	2,000	25,039	133,105
Andersen Eric	Director	Aug 08 '23	Buy	12.00	87,057	1,044,327	1,565,111
Andersen Eric	Director	Aug 07 '23	Buy	12.00	134,493	1,614,414	1,496,680

Merrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1. Its clinical program also comprises MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to solid tumors. In addition, the company is developing preclinical product candidates for various solid tumor indications. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.